KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Amortizatization of Intangibles (2016 - 2025)

Historic Amortizatization of Intangibles for Halozyme Therapeutics (HALO) over the last 13 years, with Q4 2025 value amounting to $23.4 million.

  • Halozyme Therapeutics' Amortizatization of Intangibles rose 3160.68% to $23.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $76.7 million, marking a year-over-year increase of 790.02%. This contributed to the annual value of $76.7 million for FY2025, which is 790.02% up from last year.
  • As of Q4 2025, Halozyme Therapeutics' Amortizatization of Intangibles stood at $23.4 million, which was up 3160.68% from $17.8 million recorded in Q3 2025.
  • Halozyme Therapeutics' 5-year Amortizatization of Intangibles high stood at $27.2 million for Q3 2022, and its period low was $741000.0 during Q1 2021.
  • For the 5-year period, Halozyme Therapeutics' Amortizatization of Intangibles averaged around $14.9 million, with its median value being $17.8 million (2023).
  • Its Amortizatization of Intangibles has fluctuated over the past 5 years, first tumbled by 7869.47% in 2021, then skyrocketed by 173676.62% in 2023.
  • Halozyme Therapeutics' Amortizatization of Intangibles (Quarter) stood at $968000.0 in 2021, then surged by 370.25% to $4.6 million in 2022, then surged by 290.2% to $17.8 million in 2023, then changed by 0.0% to $17.8 million in 2024, then skyrocketed by 31.61% to $23.4 million in 2025.
  • Its Amortizatization of Intangibles was $23.4 million in Q4 2025, compared to $17.8 million in Q3 2025 and $17.8 million in Q2 2025.